Combination of high-sensitivity C-reactive protein and homocysteine may predict an increased risk of coronary artery disease in Korean population

( views:96, downloads:0 )
Author:
CHO Doo-Yeoun(Department of Family Practice & Community Health, Ajou University School of Medicine, Korea)
KIM Kyu-Nam(Department of Family Practice & Community Health, Ajou University School of Medicine, Korea)
KIM Kwang-Min(Department of Family Practice & Community Health, Ajou University School of Medicine, Korea)
LEE Duck-Joo(Department of Family Practice & Community Health, Ajou University School of Medicine, Korea)
KIM Bom-Taeck(Department of Family Practice & Community Health, Ajou University School of Medicine, Korea)
Journal Title:
Chinese Medical Journal
Issue:
Volume 125, Issue 04, 2012
DOI:
10.3760/cma.j.issn.0366-6999.2012.04.002
Key Word:
C-reactive protein;homocysteine;fibrinogen;coronary artery disease

Abstract: Background The association of emerging biomarkers such as high-sensitivity C-reactive protein (hs-CRP),homocysteine and fibrinogen with the risk of coronary artery disease (CAD) is still uncertain in Asian population including Koreans and little is known about the combined effect of biomarkers on the risk of CAD.Methods A total of 10 650 subjects (6538 men and 4112 women) were enrolled in this study.A 10-year CAD risk was calculated using Framingham risk score modified by the National Cholesterol Education Program (NCEP) Adult Treatment Panel Ⅲ (ATP Ⅲ ) and levels of circulating hs-CRP,homocysteine and fibrinogen were measured using validated assays.Results The 10-year CAD risk gradually augmented with increase in the circulating levels of hs-CRP,homocysteine and fibrinogen.For the highest quartile of hs-CRP,odds ratio (OR) of high-risk for CAD (10-year risk ≥20%) compared with the lowest quartile was 3.97 (95% C/:2.51-6.29).For homocysteine and fibrinogen,ORs in the highest quartile compared to the lowest quartile were 5.10 (95% Cl:3.05-8.53,P <0.001) and 1.46 (95% Cl:0.69-3.11,P=0.325),respectively.OR of high-risk for CAD in both the highest quartile of hs-CRP and homocysteine was 9.05 (95% CI:5.30-15.45) compared with the below median of hs-CRP and homocysteine.Conclusions The present study demonstrated that hs-CRP and homocysteine are well associated with the 10-year CAD risk estimated using NCEP ATP Ⅲ in Koreans and combination of hs-CRP and homocysteine can have strong synergyin predicting the development of CAD.

  • 1.Cappuccio FP, Oakeshott P, Strazzullo P, Kerry SM.Application of Framingham risk estimates to ethnic minorities in United Kingdom and implications for primary prevention of heart disease in general practice:cross sectional population based study.BMJ 2002; 325:1271.
  • 2.Talbert RL.New therapeutic options in the National Cholesterol Education Program Adult Treatment Panel Ⅲ .Am J Manag Care 2002; 8:S301-S307.
  • 3.Pearson TA.New tools for coronary risk assessment:what are their advantages and limitations? Circulation 2002; 105:886-892.
  • 4.Boekholdt SM,Hack CE,Sandhu MS,Luben R,Bingham SA,Wareham NJ,et al.C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women:the EPIC-Norfolk prospectivepopulation study 1993-2003.Atherosclerosis 2006; 187:415-422.
  • 5.Cushman M,Arnold AM,Psaty BM,Manolio TA,Kuller LH,Burke GL,et al.C-reactive protein and the 10-year incidence of coronary heart disease in older men and women:the cardiovascular health study.Circulation 2005; 112:25-31.
  • 6.Lowe GD,Sweetnam PM,Yarnell JW,Rumley A,Rumley C,Bainton D,et al.C-reactive protein,fibrin D-dimer,and risk of ischemic heart disease:the Caerphilly and Speedwell studies.Arterioscler Thromb Vasc Bio12004; 24:1957-1962.
  • 7.Tzoulaki I,Murray GD,Lee AJ,Rumley A,Lowe GD,Fowkes FG.Relative value of inflammatory,hemostatic,and theological factors for incident myocardial infarction and stroke:the Edinburgh Artery Study.Circulation 2007; 115:2119-2127.
  • 8.Park CS,Ihm SH,Yoo KD,Kim DB,Lee JM,Kim HY,et al.Relation between C-reactive protein,homocysteine levels,fibrinogen,and lipoprotein levels and leukocyte and platelet counts,and 10-year risk for cardiovascular disease among healthy adults in the USA.Am J Cardiol 2010; 105:1284-1288.
  • 9.Ballantyne CM,Hoogeveen RC,Bang H,Coresh J,Folsom AR,Heiss G,et al.Lipoprotein-associated phospholipase A2,high-sensitivity C-reactive protein,and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study.Circulation 2004; 109:837-842.
  • 10.Helfand M,Buckley DI,Freeman M,Fu R,Rogers K,Fleming C,et al.Emerging risk factors for coronary heart disease:a summary of systematic reviews conducted for the U.S.Preventive Services Task Force.Ann Intern Med 2009;151:496-507.
  • 11.Otsuka T,Kawada T,Katsumata M,Ibuki C,Kusama Y.High-sensitivity C-reactive protein is associated with the risk of coronary heart disease as estimated by the Framingham Risk Score in middle-aged Japanese men.Int J Cardiol 2008;129:245-250.
  • 12.Arima H,Kubo M,Yonemoto K,Doi Y,Ninomiya T,Tanizaki Y,et al.High-sensitivity C-reactive protein and coronary heart disease in a general population of Japanese:the Hisayama study.Arterioscler Thromb Vasc Biol 2008; 28:1385-1391.
  • 13.Iso H,Cui R,Date C,Kikuchi S,Tamakoshi A.C-reactive protein levels and risk of mortality from cardiovascular disease in Japanese:the JACC Study.Atherosclerosis 2009;207:291-297.
  • 14.Libby P,Theroux P.Pathophysiology of coronary artery disease.Circulation 2005; 111:3481-3488.
  • 15.Friedewald WT,Levy RI,Fredrickson DS.Estimation of the concentration of low-density lipoprotein cholesterol in plasma,without use of the preparative ultracentrifuge.Clin Chem 1972; 18:499-502.
  • 16.Albert MA,Glynn RJ,Ridker PM.Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score.Circulation 2003; 108:161-165.
  • 17.Packard CJ,O'Reilly DS,Caslake MJ,McMahon AD,Ford I,Cooney J,et al.West of Scotland Coronary Prevention Study Group.Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease.N Engl J Med 2000; 343:1148-1155.
  • 18.Lawlor DA,Smith GD,Rumley A,Lowe GD,Ebrahim S.Associations of fibrinogen and C-reactive protein with prevalent and incident coronary heart disease are attenuated by adjustment for confounding factors.British Women's Heart and Health Study.Thromb Haemost 2005; 93:955-963.
  • 19.Mehta JL,Saldeen TG,Rand K.Interactive role of infection,inflammation and traditional risk factors in atherosclerosis and coronary artery disease.J Am Coll Cardiol 1998; 31:1217-1225.
  • 20.Ross R.Atherosclerosis is an inflammatory disease.Am Heart J 1999; 138:S419-S420.
  • 21.Castell JV, Gomez-Lechon MJ, David M, Fabra R,Trullenque R,Heinrich PC.Acute-phase response of human hepatocytes:regulation of acute-phase protein synthesis by interleukin-6.Hepatology 1990; 12:1179-1186.
  • 22.Mayer EL,Jacobsen DW,Robinson K.Homocysteine and coronary atherosclerosis.J Am Coll Cardiol 1996; 27:517-527.
  • 23.Anand SS,Razak F.Yi Q,Davis B,Jacobs R,Vuksan V,et al.C-reactive protein as a screening test for cardiovascular risk in a multiethnic population.Arterioscler Thromb Vasc Biol 2004; 24:1509-1515.
  • 24.Allison MA,Criqui MH,McClelland RL,Scott JM,McDermott MM,Liu K,et al.The effect of novel cardiovascular risk factors on the ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA).J Am Coll Cardiol 2006; 48:1190-1197.
  • 25.Pearson TA,Mensah GA,Alexander RW,Anderson JL,Cannon RO 3rd,Criqui M,et al.Markers of inflammation and cardiovascular disease:application to clinical and public health practice:a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.Circulation 2003; 107:499-511.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn